Cytokines in cancer immunity and immunotherapy

被引:311
作者
Smyth, MJ [1 ]
Cretney, E [1 ]
Kershaw, MH [1 ]
Hayakawa, Y [1 ]
机构
[1] Peter MacCallum Canc Ctr, Trescowthick Labs, Canc Immunol Program, Melbourne, Vic 8006, Australia
关键词
D O I
10.1111/j.0105-2896.2004.00199.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The concept that the immune system recognizes and controls cancer was first postulated over a century ago, and cancer immunity has continued to be vigorously debated and experimentally tested. Mounting evidence in humans and mice supports the involvement of cytokines in tumor initiation, growth, and metastasis. The idea that the immune system detects stressed, transformed, and frankly malignant cells underpins much of the excitement currently surrounding new cytokine therapies in cancer treatment. In this review, we define the contrasting roles that cytokines play in promoting tumor immunity, inflammation, and carcinogenesis. We also discuss the more promising aspects of clinical cytokine use in cancer patients.
引用
收藏
页码:275 / 293
页数:19
相关论文
共 213 条
[1]  
Agarwala S S, 2000, Forum (Genova), V10, P230
[2]   INTERFERONS IN THE THERAPY OF SOLID TUMORS [J].
AGARWALA, SS ;
KIRKWOOD, JM .
ONCOLOGY, 1994, 51 (02) :129-136
[3]   Tickling memory T cells [J].
Ahmed, R .
SCIENCE, 1996, 272 (5270) :1904-1904
[4]   Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver [J].
Alexander, HR ;
Bartlett, DL ;
Libutti, SK ;
Fraker, DL ;
Moser, T ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1479-1489
[5]   Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency [J].
Altare, F ;
Durandy, A ;
Lammas, D ;
Emile, JF ;
Lamhamedi, S ;
Le Deist, F ;
Drysdale, P ;
Jouanguy, E ;
Döffinger, R ;
Bernaudin, F ;
Jeppsson, O ;
Gollob, JA ;
Meinl, E ;
Segal, AW ;
Fischer, A ;
Kumararatne, D ;
Casanova, JL .
SCIENCE, 1998, 280 (5368) :1432-1435
[6]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[7]   Interleukin-1 - a major pleiotropic cyrtokine in tumor-host interactions [J].
Apte, RN ;
Voronov, E .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (04) :277-290
[8]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[9]  
Atkins MB, 2000, CANCER J SCI AM, V6, pS11
[10]   Tumor necrosis factor or tumor promoting factor? [J].
Balkwill, F .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :135-141